BillionToOne Q2 Revenue Jumps 64% to $109.4M, Swings to Profit; Reiterates 2026 Guidance
BLLN sits 72% above its 52-week low of $61.96.
Summary
BillionToOne reported Q2 2026 revenue of $109.4M (+64% YoY), net income of $8.1M, and 70% gross margins. Full-year 2026 revenue guidance of $450M–$465M was reiterated.
Key Events · Earnings and Guidance · BLLN
-
Revenue Surges 64% to $109.4M
Total Q2 revenue reached $109.4 million, driven by 55% growth in prenatal testing ($94.2M) and 176% growth in oncology testing ($13.7M).
-
Swings to Profitability
Net income was $8.1 million ($0.15 per diluted share) versus a net loss of $0.2 million in Q2 2025, with operating income of $5.5 million.
-
Gross Margin Expands to 70%
Gross margin improved 5 percentage points year-over-year to 70%, reflecting higher average selling prices and operating leverage.
-
Full-Year Guidance Reiterated
Management reaffirmed 2026 revenue guidance of $450–$465 million, representing 48–52% growth, and expects to maintain profitability.
Analysis · BLLN · Industrial Applications And Services
A standout quarter saw revenue climb 64% year-over-year to $109.4 million, while the bottom line swung to a net profit of $8.1 million from a loss a year ago. Gross margins expanded to 70%, and the company generated positive free cash flow. Management reiterated full-year 2026 revenue guidance of $450–$465 million, implying 48–52% growth, and expects to sustain profitability. The results validate commercial momentum in both prenatal and oncology testing, with upcoming product launches poised to further expand the addressable market.
At the time of this filing, BLLN was trading at $106.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.9B. The 52-week trading range was $61.96 to $150.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.